ArticleNeurotoxicity research2026
Silymarin Reverses Seizure-Precipitating Effects of Alcohol and Associated Psychiatric Comorbidities, and Neurotoxicity in Pentylenetetrazol Pre-Kindled Mice.
Article in Neurotoxicity research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heavy alcohol consumption has multiple negative cognitive, psychological, and neurobiological consequences for people with epilepsy. However, the psychopharmacological interactions remain unclear with limited therapeutic interventions. In this study, we investigated the diverse impact of alcohol on experimental simulated pentylenetetrazol-induced seizures and alcohol-use disorder, and the effects of silymarin, a polyphenolic compound with neuroprotective properties. Following seven days of ethanol binge exposure (2 g/kg, oral gavage) in mice, maximal and sub-convulsive pentylenetetrazol-induced seizures were administered from days 8 to 14, alongside silymarin (50 and 100 mg/kg) or diazepam (3 mg/kg) oral administration. This study evaluated the interplay between ethanol and pentylenetetrazol-induced seizures, assessing behavioural comorbidities, dysregulation of the hypothalamic-pituitary-adrenal (HPA)-axis, neurochemical and neurotrophic alterations, oxidative stress, and neuroinflammation in the hippocampus, prefrontal-cortex, and striatum, which are involved in the disease. Ethanol increased seizure severity and frequency caused by pentylenetetrazol, and worsened anxiety-like and depressive behaviours, along with spatial working memory deficits linked to higher alcohol preference. These effects were reduced by silymarin. Ethanol also increased corticosterone release and reduced GABA-dependent glutamic acid decarboxylase activity, raising glutamate levels, while decreasing serotonin and brain-derived neurotrophic factor across the studied brain regions. Silymarin significantly reduced neuroinflammatory markers such as myeloperoxidase, TNF-α, IL-6, nitrite, and malondialdehyde, while enhancing IL-10 levels and antioxidant defenses, including catalase, superoxide dismutase and glutathione in the brain regions. These findings suggest alcoholism with alcohol-use disorders worsens epilepsy, notably involving neurochemical imbalance, neurotropic, HPA-axis upregulation, oxidative stress, and neuroinflammation, which were reversed by silymarin.
Indexed as
Identifiers
42399577What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.